Resmed
RMD
$204.15
+1.12%
ResMed Inc. is a global leader in the development and supply of medical devices and software solutions for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions, operating within the Medical Instruments & Supplies industry. The company has established a distinct competitive identity as a dominant market leader in sleep therapy, further differentiated by its strategic push into digital health platforms that connect patients, providers, and payers with clinical data. The current investor narrative is dominated by the company's execution within a structurally growing market driven by rising diagnosis rates, but also by recent stock price weakness, which has sparked debate over whether this represents a cyclical pullback or a more fundamental reassessment of growth and margin prospects in the face of potential competitive and macroeconomic pressures.…
RMD
Resmed
$204.15
Investment Opinion: Should I buy RMD Today?
Rating & Thesis: Hold. ResMed is a high-quality company caught in a valuation reset, offering compelling long-term value but facing near-term momentum headwinds that advise patience. The analyst consensus, while mixed, implies a ~33% upside to an average target near $268, anchoring a positive medium-term view.
Supporting Evidence: This Hold rating is supported by four key data points: 1) The forward P/E of 16.61x is attractive for a company with a 23.5% ROE, 2) Revenue growth remains solid at 11% YoY, 3) Profitability is exceptional with net margins of 27.6%, and 4) The balance sheet is pristine with a 3.44 current ratio and $1.79B in TTM FCF. The PEG ratio of 0.72 further suggests growth is not fully priced in.
Risks & Conditions: The two biggest risks are a breakdown of the $198.61 support level triggering further technical selling, and a deceleration of quarterly revenue growth below 8% YoY. This Hold would upgrade to a Buy if the stock stabilizes above support and the forward P/E compresses further towards 15x on sustained earnings growth, or downgrade to a Sell if revenue growth decelerates sharply or gross margins fall below 58%. At current levels, the stock appears fairly valued to slightly undervalued relative to its own growth profile but remains overvalued on a trailing basis compared to more stagnant peers.
Sign up to view all
RMD 12-Month Price Forecast
The AI assessment is neutral with medium confidence. ResMed's investment case is bifurcated: its operational and financial metrics are characteristic of a strong Buy, but its price action and sentiment are characteristic of a Sell. The forward valuation has become attractive, pricing in significant skepticism. The stance would upgrade to Bullish on a confirmed technical reversal (e.g., a weekly close above the 50-day moving average) coupled with stable quarterly margins. It would downgrade to Bearish on a confirmed breakdown below the $198 support level with deteriorating fundamentals. For now, the weight of evidence suggests the sell-off is overdone, but momentum must be respected.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Resmed's 12-month outlook, with a consensus price target around $265.40 and implied upside of +30.0% versus the current price.
Average Target
$265.40
12 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
12
covering this stock
Price Range
$163 - $265
Analyst target range
ResMed is covered by 14 analysts, indicating substantial institutional interest. The consensus sentiment appears mixed but leans cautiously optimistic, with recent actions including a downgrade from Baird to 'Neutral' in December 2025, though maintained 'Outperform' or 'Overweight' ratings from firms like RBC Capital and Keybanc. The average target price implied by the estimated EPS and forward PE suggests a value of approximately $268 (16.61 forward PE * $16.15 estimated EPS), which would represent a significant upside of roughly +33% from the current price of $201.88, though a formal consensus target price is not explicitly provided in the data. The target range, inferred from estimated EPS, spans from a low of $15.91 to a high of $16.34, which, when applied to the forward PE, implies a relatively tight range; this narrower spread suggests analysts have a higher degree of conviction in the near-term earnings trajectory, with the high target likely assuming successful execution on growth and margin initiatives, while the low target may factor in competitive or reimbursement pressures.
Bulls vs Bears: RMD Investment Factors
The evidence presents a classic battle between strong fundamentals and weak technicals. The bull case, supported by robust profitability, a healthy balance sheet, and an attractive forward valuation with 33% implied upside, appears fundamentally stronger. However, the bear case, driven by severe price momentum, elevated trailing multiples, and high short interest, has dominated recent price action. The single most important tension is whether the current ~27x trailing P/E multiple accurately reflects a high-quality, growing business experiencing a temporary setback, or if it presages a more permanent de-rating due to slowing growth or competitive encroachment. The resolution of this valuation debate will likely determine the stock's direction.
Bullish
- Strong Fundamentals and Profitability: ResMed generates robust profitability with a net margin of 27.59% and a gross margin of 62.18% in its latest quarter, which improved sequentially from 59.36%. This operational efficiency is supported by a high return on equity of 23.47% and substantial free cash flow of $1.79 billion TTM, providing a strong financial foundation.
- Attractive Valuation Relative to Growth: The stock's forward P/E of 16.61x implies a significant discount to its trailing P/E of 27.02x, reflecting market expectations for strong earnings growth. The PEG ratio of 0.72, based on trailing P/E, suggests the stock is undervalued relative to its growth prospects, especially when compared to sector averages.
- Significant Analyst Target Upside: The average analyst target price, implied by the forward P/E and estimated EPS of $16.15, is approximately $268. This represents a potential upside of +33% from the current price of $201.88, indicating a strong consensus view that the stock is undervalued at current levels.
- Healthy Balance Sheet with Low Debt: The company maintains a fortress balance sheet with a low debt-to-equity ratio of 0.14 and a strong current ratio of 3.44. This minimal leverage and high liquidity provide ample flexibility to navigate economic cycles, invest in growth, and return capital to shareholders without financial stress.
Bearish
- Severe Negative Price Momentum: The stock is in a pronounced downtrend, down 20.06% over the past three months and 18.79% over the past year, significantly underperforming the S&P 500 by -28.48% and -43.98% over those periods, respectively. Trading just 1.6% above its 52-week low of $198.61 signals deep investor pessimism and negative momentum.
- Elevated Trailing Valuation Multiples: Despite the recent sell-off, the trailing P/E of 27.02x remains elevated compared to many medical device peers. This premium valuation leaves the stock vulnerable to further multiple compression if growth expectations are not met or if sector-wide de-rating occurs.
- High Short Interest Indicating Skepticism: A short ratio of 11.67 indicates a significant level of bearish bets against the stock. This high short interest reflects market skepticism about the company's near-term prospects and could lead to increased volatility, especially on any negative news.
- Recent Analyst Downgrade and Mixed Sentiment: Analyst sentiment has turned cautious, evidenced by a recent downgrade from Baird to 'Neutral' in December 2025. While the average target implies upside, this action suggests growing concerns about competitive pressures or growth deceleration that could cap near-term performance.
RMD Technical Analysis
The prevailing price trend for ResMed is a pronounced and sustained downtrend, with the stock down 18.79% over the past year and trading near the bottom of its 52-week range. With a current price of $201.88, it is positioned just 1.6% above its 52-week low of $198.61, indicating the stock is in deeply oversold territory and may represent a potential value opportunity, though it also signals significant negative momentum and investor pessimism. Recent momentum has been sharply negative and accelerating, with the stock declining 11.77% over the past month and 20.06% over the past three months, a stark divergence from the broader market's positive performance as evidenced by a -17.37 relative strength figure over one month. This severe underperformance suggests the downtrend is intensifying, potentially driven by company-specific concerns rather than broader market conditions. Key technical levels are clearly defined, with immediate support at the 52-week low of $198.61 and major resistance far above at the 52-week high of $293.81; a breakdown below the $198 support could trigger further technical selling, while any recovery would need to overcome significant overhead supply. The stock's beta of 0.845 indicates it is historically 15.5% less volatile than the S&P 500, making its recent severe underperformance particularly notable and suggesting idiosyncratic risk factors are at play.
Beta
0.84
0.84x market volatility
Max Drawdown
-32.3%
Largest decline past year
52-Week Range
$199-$294
Price range past year
Annual Return
-18.9%
Cumulative gain past year
| Period | RMD Return | S&P 500 |
|---|---|---|
| 1m | -10.5% | +4.0% |
| 3m | -20.2% | +8.2% |
| 6m | -16.7% | +11.5% |
| 1y | -18.9% | +24.3% |
| ytd | -16.6% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RMD Fundamental Analysis
ResMed's revenue trajectory shows consistent growth, with the most recent quarterly revenue of $1.42 billion representing a 10.98% year-over-year increase, and sequential growth from the prior quarter's $1.34 billion. The multi-quarter trend is positive, with revenue climbing from $1.19 billion in Q3 2024 to the current level, indicating the core sleep and respiratory business is driving steady top-line expansion, supported by the smaller but strategic Residential Care Software segment which contributed $166.87 million. The company is highly profitable, reporting net income of $392.59 million for the quarter and a robust gross margin of 62.18%, which has improved from 59.36% in the prior quarter. Operating margins are also strong at 34.97%, and the net margin of 27.59% reflects efficient operations, though investors will monitor for any compression as the company invests in growth and digital initiatives. The balance sheet and cash flow position is exceptionally healthy, with a low debt-to-equity ratio of 0.14, a strong current ratio of 3.44, and substantial free cash flow generation of $1.79 billion on a trailing twelve-month basis; this robust financial health, coupled with a return on equity of 23.47%, indicates the company generates ample cash to fund growth, return capital to shareholders, and navigate economic cycles without reliance on external financing.
Quarterly Revenue
$1.4B
2025-12
Revenue YoY Growth
+0.10%
YoY Comparison
Gross Margin
+0.62%
Latest Quarter
Free Cash Flow
$1.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RMD Overvalued?
Given ResMed's substantial net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 27.02x and a forward PE of 16.61x based on estimated EPS. The significant gap between trailing and forward multiples implies the market expects robust earnings growth in the coming year, effectively pricing in a forward earnings increase. Compared to sector averages, ResMed's valuation presents a mixed picture; its trailing PE of 27.02x is elevated relative to many medical device peers, but its forward PE of 16.61x and a PEG ratio of 0.72 (based on trailing PE) suggest the premium may be justified by its above-average growth profile, high profitability, and market-leading position. Historically, the current trailing PE of 27.02x sits below the stock's own recent historical range observed in the provided data, which has seen PEs fluctuate from the low 20s to over 30x in recent quarters; this positioning near the lower end of its historical band suggests the market may be pricing in more conservative expectations or a growth slowdown, potentially offering a more attractive entry point if the company's fundamental growth story remains intact.
PE
27.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -90x~50x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: ResMed's primary financial risk is not leverage or liquidity, given its strong balance sheet (D/E 0.14), but rather its dependence on sustaining high growth and margins to justify its valuation. The trailing P/E of 27x is a premium that demands consistent execution; any deceleration from the recent 11% revenue growth or compression from the 62% gross margin would disproportionately impact earnings and the stock price. Furthermore, while geographically diversified, the company's revenue is concentrated in sleep therapy devices, making it susceptible to product-specific competitive or reimbursement pressures.
Market & Competitive Risks: The stock faces significant valuation compression risk, as its current trailing P/E of 27.02x sits at the lower end of its own historical range but remains elevated versus peers. Its beta of 0.845 indicates it is less volatile than the market historically, yet its severe recent underperformance (-17.37 relative strength over one month) suggests idiosyncratic risks are at play, such as fears of market share loss or regulatory changes affecting the sleep apnea treatment landscape. The high short ratio of 11.67 amplifies these risks, as coordinated short-selling can exacerbate downturns.
Worst-Case Scenario: The worst-case scenario involves a combination of failed growth initiatives, increased competitive pressure from rivals like Philips, and potential reimbursement headwinds from payers, leading to a simultaneous slowdown in revenue growth to mid-single digits and margin contraction. This could trigger a wave of analyst downgrades and a de-rating towards the sector's lower valuation range. Realistic downside could see the stock re-test and break its 52-week low of $198.61, potentially falling towards a bear-case P/E in the low 20s applied to lowered earnings, implying a further decline of 15-20% from current levels, for a total peak-to-trough drawdown exceeding the recent -32.33%.
FAQ
The key risks are, in order of severity: 1) Valuation/Momentum Risk: The stock is in a severe downtrend (-20% over 3 months) and a breakdown below $198.61 support could trigger further technical selling. 2) Competitive/Growth Risk: Any deceleration from the current 11% revenue growth or compression from the 62% gross margin would challenge its premium valuation. 3) Sentiment Risk: High short interest (short ratio 11.67) increases volatility and reflects deep market skepticism. 4) Sector Risk: As a medical device stock, it is subject to regulatory changes and reimbursement pressures from healthcare payers.
The 12-month forecast is scenario-dependent with a neutral base case. The Bull Case (30% probability) sees the stock reaching $268-$293 on successful execution and multiple expansion. The Base Case (50% probability), which is most likely, anticipates consolidation in the $230-$268 range as the company delivers steady growth. The Bear Case (20% probability) warns of a test of the $198 low and potential movement into the $198-$220 range if fundamentals deteriorate. The key assumption behind the base case is that ResMed maintains its current ~11% revenue growth and ~62% gross margin profile, allowing the attractive forward P/E to provide a valuation floor.
RMD's valuation is mixed, presenting a tale of two multiples. On a trailing basis, its P/E of 27.02x is elevated and suggests the stock is overvalued compared to historical sector averages. However, its forward P/E of 16.61x and PEG ratio of 0.72 indicate it is undervalued relative to its expected earnings growth. Compared to its own historical range, the current trailing P/E is at the lower end, suggesting the market has already priced in a more conservative outlook. Overall, the stock appears fairly valued to slightly undervalued on a forward-looking basis, but carries the overhang of a high trailing multiple.
RMD presents a compelling but nuanced opportunity. For long-term, patient investors, the current price near a 52-week low and a forward P/E of 16.6x for a company with 27.6% net margins and 11% growth represents good value. The average analyst target implies +33% upside. However, the severe negative momentum, high short interest, and risk of further growth deceleration make it a higher-risk buy at this moment. It is a good buy for investors who believe the fundamental story remains intact and are willing to average in or wait for a confirmed bottom in price action.
RMD is primarily suitable for a long-term investment horizon of 3-5 years. Its low dividend yield (0.82%) and current lack of positive momentum make it a poor candidate for short-term trading or income. The investment thesis is based on the company's durable competitive position in a growing market, its high profitability, and the expectation that the current valuation discount will normalize over time. Given its beta of 0.85 and strong fundamentals, it can serve as a defensive growth holding in a long-term portfolio. A minimum holding period of 18-24 months is suggested to allow for the operational story to unfold and for the technical damage to repair.
